Aspartate aminotransferase to platelet ratio and fibrosis‐4 as biomarkers in biopsy‐validated pediatric cystic fibrosis liver disease

Daniel H. Leung, Mahjabeen Khan, Charles G. Minard, Danielle Guffey, Louise E. Ramm, Andrew D. Clouston, Gregory Miller, Peter J. Lewindon, Ross W. Shepherd, Grant A. Ramm – 29 July 2015 – Up to 10% of cystic fibrosis (CF) children develop cirrhosis by the first decade. We evaluated the utility of two simple biomarkers, aspartate aminotransferase to platelet ratio index (APRI) and FIB‐4, in predicting degree of fibrosis in pediatric CF liver disease (CFLD) validated by liver biopsy.

The UK‐PBC risk scores: Derivation and validation of a scoring system for long‐term prediction of end‐stage liver disease in primary biliary cholangitis

Marco Carbone, Stephen J. Sharp, Steve Flack, Dimitrios Paximadas, Kelly Spiess, Carolyn Adgey, Laura Griffiths, Reyna Lim, Paul Trembling, Kate Williamson, Nick J. Wareham, Mark Aldersley, Andrew Bathgate, Andrew K. Burroughs, Michael A. Heneghan, James M. Neuberger, Douglas Thorburn, Gideon M. Hirschfield, Heather J. Cordell, Graeme J. Alexander, David E.J. Jones, Richard N. Sandford, George F.

Randomized, controlled trial of entecavir versus placebo in children with hepatitis B envelope antigen–positive chronic hepatitis B

Maureen M. Jonas, Mei‐Hwei Chang, Etienne Sokal, Kathleen B. Schwarz, Deirdre Kelly, Kyung Mo Kim, Simon C. Ling, Philip Rosenthal, Dumitru Oraseanu, Laurie Reynolds, Alexandra Thiry, Peter Ackerman – 29 July 2015 – This ongoing, randomized phase III study assesses the safety and efficacy of entecavir versus placebo in nucleos(t)ide‐naïve children (2 to <18 years) with hepatitis B envelope antigen (HBeAg)‐positive chronic hepatitis B (CHB). Blinded treatment was administered for a minimum of 48 weeks.

Subscribe to